Table 1

Sample selection and attrition
Patients Remaining
N %
Patients* 151,118
Patients with continuous enrollment (index date minus 365 to index date) 72,978 48.3
Patients with index cancer (BC, CRC, LC, NHL, Ovarian) 18,186 24.9
Patients meeting criteria for eligible course 10,219 56.2
Patients without stem cell transplant 10,207 99.9
Patients without use of nursing facility 9,989 97.9
Patients with G-CSF use during at least one cycle 4,684 46.9
Patients without radiation on index date 4,531 96.7
Patients without more than one primary cancer site 3,958 87.4
Patients with prophylactic G-CSF use in at least one cycle 3,535 89.3
 Patients with prophylactic pegfilgrastim use 3,372 95.4
 Patients with prophylactic filgrastim use 163 4.6
Patient-cycles with G-CSF prophylaxis in 3,535 patients 12,056
 Pegfilgrastim 11,683 96.9
 Filgrastim 373 3.1
Patient-cycles with G-CSF prophylaxis [included up to the 9th cycle] 11,968
 Pegfilgrastim 11,597 96.9
 Filgrastim 371 3.1

BC – breast cancer, CRC – colorectal cancer, LC – lung cancer, and NHL – non-Hodgkin’s lymphoma.

* Patients with any evidence of chemotherapy from January 1, 2005 to February 28, 2009 (index date set to first administration) and no chemotherapy from index date −365 to index date −1.

Primary cancers defined as: 140.xx – 172.xx, 174.xx – 195.xx and 199.xx – 208.xx.

Naeim et al.

Naeim et al. BMC Cancer 2013 13:11   doi:10.1186/1471-2407-13-11

Open Data